Home > Archive>Volume 22, Issue 11, 2022 >1800-1803. DOI:10.3980/j.issn.1672-5123.2022.11.07
PDF HTML XML Export Cite reminder
Development status of dropless cataract surgery
Author:
Fund Project:

National Natural Science Foundation of China(No.81870644); Hunan Clinical Medical Technology Innovation Guidance Project(No.2020SK50102); Scientific Research Project of Shenyang Health Commission in 2020(No.2020103); Research Fund Project of Aier Institute of Cataract and Intraocular Lens(No.AR2002D7)

  • Article
    • | |
  • Metrics
    • |
  • Reference [31]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    As cataract surgery has entered the era of minimally invasive and accurate refractive surgery, higher requirements for perioperative infection control are needed. In recent years, “dropless cataract surgery” has been proposed and is gradually applied in clinical practice. It is based on the combination of different local injection forms in cataract surgery, in which antibiotics and steroids are applied to the operative eye through immediate or sustained release, so that patients do not need to use eye drops throughout the perioperative period.It can not only achieve the purpose of anti-inflammation and anti-infection after surgery, but also reduce the burden of patients, patients' family members and doctors.This article reviews the concept of “dropless cataract surgery”, the combined treatment methods, including combined anterior chamber antibiotic injection, triamcinolone acetonide and moxifloxacin hydrochloride(TriMoxi)and triamcinolone -moxifloxacin and vancomycin(TriMoxiVanc)intravitreal injection, combined dexamethasone lacrimal puncture implantation, continuous or sustained release drug delivery mechanism, as well as its efficacy and safety, with a view to provide a new idea and direction for the prevention of postoperative cataract infection.

    Reference
    1 Schwartz SG, Grzybowski A, Flynn HW Jr. Antibiotic prophylaxis: different practice patterns within and outside the United States. Clin Ophthalmol 2016; 10:251-256
    2中华医学会眼科学分会白内障与人工晶状体学组. 我国白内障术后急性细菌性眼内炎治疗专家共识(2010年). 中华眼科杂志 2010; 46(8):764-766
    3 Zafar S, Wang PQ, Schein OD, et al. Prescribing patterns and costs associated with postoperative eye drop use in medicare beneficiaries undergoing cataract surgery. Ophthalmology 2020; 127(5):573-581
    4 Newman-Casey PA, Dayno M, Robin AL. Systematic review of educational interventions to improve glaucoma medication adherence: an update in 2015. Expert Rev Ophthalmol 2016; 11(1):5-20
    5 Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence. Ophthalmology 2015; 122(7):1308-1316
    6 Dietlein TS, Jordan J, Dinslage S, et al. What do glaucoma specialists know about their patients? Graefes Arch Clin Exp Ophthalmol 2006; 244(7):859-862
    7 Feng A, O'Neill J, Holt M, et al. Success of patient training in improving proficiency of eyedrop administration among various ophthalmic patient populations. Clin Ophthalmol 2016; 10:1505-1511
    8 Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29(4):312-334
    9 Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol 2013; 7:2131-2135
    10 An JA, Kasner O, Samek DA, et al. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg 2014; 40:1857-1861
    11卢奕, 郑天玉. 前房内注射抗生素预防白内障摘除手术后眼内炎的意义. 中华眼科杂志 2018; 54(5): 339-342
    12 Shorstein NH, Winthrop KL, Herrinton LJ. Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg 2013; 39(1):8-14
    13 Barry P, Seal DV, Gettinby G, et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery. J Cataract Refract Surg 2006; 32(3):407-410
    14 Matsuura K, Miyoshi T, Suto C, et al. Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan. J Cataract Refract Surg 2013; 39(11):1702-1706
    15 Haripriya A, Chang DF, Namburar S, et al. Efficacy of intracameral moxifloxacin endophthalmitis prophylaxis at aravind eye hospital. Ophthalmology 2016; 123(2):302-308
    16 Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin in eyes with and without surgical complications: results from 2 million consecutive cataract surgeries. J Cataract Refract Surg 2019; 45(9):1226-1233
    17 Bowen RC, Zhou AX, Bondalapati S, et al. Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis. Br J Ophthalmol 2018; 102(9):1268-1276
    18 Huang JZ, Wang XF, Chen XH, et al. Perioperative antibiotics to prevent acute endophthalmitis after ophthalmic surgery: a systematic review and Meta-analysis. PLoS One 2016; 11(11):e0166141
    19 Kessel L, Flesner P, Andresen J, et al. Antibiotic prevention of postcataract endophthalmitis: a systematic review and meta-analysis. Acta Ophthalmol 2015; 93(4):303-317
    20 Golozar A, Chen YJ, Lindsley K, et al. Identification and description of reliable evidence for 2016 American academy of ophthalmology preferred practice pattern guidelines for cataract in the adult eye. JAMA Ophthalmol 2018; 136(5):514-523
    21 Murphy CC, Nicholson S, Quah SA, et al. Pharmacokinetics of vancomycin following intracameral bolus injection in patients undergoing phacoemulsification cataract surgery. Br J Ophthalmol 2007; 91(10):1350-1353
    22 Lindstrom RL, Galloway MS, Grzybowski A, et al. Dropless cataract surgery: an overview. Curr Pharm Des 2017; 23(4):558-564
    23 Singhal R, Luo A, O'Rourke T, et al. Transzonular triamcinolone-moxifloxacin versus topical drops for the prophylaxis of postoperative inflammation after cataract surgery. J Ocul Pharmacol Ther 2019; 35(10):565-570
    24 Blizzard C, Desai A, Driscoll A. Pharmacokinetic studies of sustained-release depot of dexamethasone in beagle dogs. J Ocul Pharmacol Ther 2016; 32(9):595-600
    25 Driscoll A, Blizzard C. Toxicity and pharmacokinetics of sustained-release dexamethasone in beagle dogs. Adv Ther 2016; 33(1):58-67
    26 Ocular Therapeutix, Inc. Ocular Therapeutix? Announces Commercial Launch of DEXTENZA?(dexamethasone intracanalicular insert)0.4 mg for Ophthalmic Use in the United States.Business Wire(English).2019.https://www.dextenza.com/
    27 Lee A, Blair HA. Dexamethasone intracanalicular insert: a review in treating post-surgical ocular pain and inflammation. Drugs 2020; 80(11):1101-1108
    28 Gira JP, Sampson R, Silverstein SM, et al. Evaluating the patient experience after implantation of a 0.4Mg sustained release dexamethasone intracanalicular insert(DextenzaTM):results of a qualitative survey. Patient Prefer Adherence 2017; 11:487-494
    29 Donnenfeld E, Holland E. Dexamethasone intracameral drug-delivery suspension for inflammation associatedwith cataract surgery: a randomized, placebo-controlled, phase III trial. Ophthalmology 2018; 125(6):799-806
    30 Filipe HP, Bozukova D, Pimenta A, et al. Moxifloxacin-loaded acrylic intraocular lenses: In vitro and in vivo performance. J Cataract Refract Surg 2019; 45(12):1808-1817
    31 Pimenta AFR, Serro AP, Colaço R, et al. Drug delivery to the eye anterior chamber by intraocular lenses: an in vivo concentration estimation model. Eur J Pharm Biopharm 2018; 133:63-69
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Dong Han, Jing Wang, Zhen-Bo Zhao,/et al.Development status of dropless cataract surgery. Guoji Yanke Zazhi( Int Eye Sci) 2022;22(11):1800-1803

Copy
Share
Article Metrics
  • Abstract:490
  • PDF: 975
  • HTML: 0
  • Cited by: 0
Publication History
  • Received:March 02,2022
  • Revised:October 08,2022
  • Online: October 28,2022
You are the 26464 Visitors
Governing Body：Department of Health, Provincial Government of Shaanxi, China
Organizer：Xi'an Medical Association of China
Address：Room 11707-08, Building 2, Unit 1, Wanda Plaza, No.8 Yanta North Road, Xi'an 710054, Shaanxi Province, China
Fax：(8629)82245172 Phone：(+8629)82245172/82210956
Email：ijopress@163.com
® 2025 All Rights Reserved   The terms of CC BY-NC-ND 4.0 are applicable to all open access content.